Swedish Orphan Biovitrum Second Quarter 2025 Earnings: Revenues In Line With Expectations

Swedish Orphan Biovitrum (STO:SOBI) Second Quarter 2025 Results

Key Financial Results

• Revenue: kr6.18b (up 14% from 2Q 2024).
• Net income: kr636.0m (up 184% from 2Q 2024).
• Profit margin: 10% (up from 4.1% in 2Q 2024). The increase in margin was driven by higher revenue.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Swedish Orphan Biovitrum Meets Expectations

Revenue was in line with analyst estimates.

Looking ahead, revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Sweden.

Performance of the Swedish Biotechs industry.

The company's shares are down 6.3% from a week ago.

Risk Analysis

Be aware that Swedish Orphan Biovitrum is showing 1 warning sign in our investment analysis that you should know about...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.